Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
ADM
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "ADM" in MCE Product Catalog:
4
Category:
1
1 Cited Publications
Cat. No.: HY-P99177
CAS No.: 2305638-98-4
Target:
Research Areas:
1
Cat. No.: HY-N1514
CAS No.: 100665-41-6
Category:
Triterpenes Human Gut Microbiota Metabolites Microorganisms Terpenoids Polyporaceae Extract Plants Endogenous metabolite Disease Research Fields Cancer
Target:
Cat. No.: HY-P1838
CAS No.: 166798-69-2
Target:
Research Areas:
Cat. No.: HY-P3919
CAS No.: 166546-72-1
Synonyms: Pro-ADM-153-185 (human)
Target:
Research Areas:
Cat. No.: HY-124277
CAS No.: 1644134-60-0
Target:
Research Areas:
ADM 12 is a highly selective transient receptor potential ankyrin 1 (TRPA1) channel antagonist. ADM 12 blocks nitroglycerin (NTG)-induced trigeminal hyperalgesia in animal models, reducing expression of pain-related genes (c-Fos, TRPA1) and neuropeptides (CGRP, SP). ADM_12 is promising for research of migraine and neuropathic pain .
Cat. No.: HY-P3919A
Synonyms: Pro-ADM-153-185 (human) TFA
Target:
Research Areas:
Cat. No.: HY-178349
Target:
Research Areas:
P-gp inhibitor 30 is a potent P-gp inhibitor that reverses multidrug resistance in breast cancer by sensitizing resistant cells to Doxorubicin (ADM) (HY-15142). P-gp inhibitor 30 promotes apoptosis, induces autophagy, and suppresses proliferation, migration, and invasion of drug-resistant breast cancer cells when combined with ADM. P-gp inhibitor 30 inhibits breast tumor growth both in vitro and in vivo. P-gp inhibitor 30 can be used for drug-resistant breast cancer research .
Cat. No.: HY-174469
CAS No.: 3070438-79-5
Target:
PROTACs Apoptosis PI3K Akt Bcl-2 Family P-glycoprotein Reactive Oxygen Species (ROS) Na+/K+ ATPase
Research Areas:
PROTAC PI3K/110β degrader-2 is a VHL-recruiting PI3K/110β PROTAC degrader, with DC50 values of 1.258 μM and 2.185 μM in MCF-7/ADM and A549/DDP cells, respectively. PROTAC PI3K/110β degrader-2 induces proteasomal degradation of PI3K/110β, inhibits phosphorylation of AKT and expression of Bcl-2, while suppressing the activity and expression of P-gp. It also induces endoplasmic reticulum stress and mitochondrial apoptosis via the PERK/CHOP pathway. PROTAC PI3K/110β degrader-2 exerts anti-tumor activity against multidrug-resistant cancer cells both in vitro and in vivo, and produces a synergistic effect when combined with Doxorubicin (HY-15142A) or Cisplatin (HY-17394), making it applicable for the research of multidrug-resistant cancers .
Cat. No.: HY-RS00386
Target:
Research Areas:
ADM Human Pre-designed siRNA Set A contains three designed siRNAs for ADM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23391
Target:
Research Areas:
Adm Rat Pre-designed siRNA Set A contains three designed siRNAs for Adm gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00387
Target:
Research Areas:
ADM2 Human Pre-designed siRNA Set A contains three designed siRNAs for ADM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS00388
Target:
Research Areas:
ADM5 Human Pre-designed siRNA Set A contains three designed siRNAs for ADM5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS20246
Target:
Research Areas:
Adm2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Adm2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS26754
Target:
Research Areas:
Adm2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Adm2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-176421
CAS No.: 3070438-85-3
Target:
PROTACs PI3K Apoptosis Akt Bcl-2 Family Caspase P-glycoprotein
Research Areas:
PROTAC PI3K/110β degrader-1 is a VHL-recruiting PROTAC degrader targeting PI3K/110β, with DC50 values of 0.416 μM (MCF-7) and 19.66 μM (A549), respectively. PROTAC PI3K/110β degrader-1 recruits VHL to induce proteasomal degradation of PI3K/110β. It activates endoplasmic reticulum stress (ERS)-mediated mitochondrial apoptosis via the PERK/ATF4/CHOP unfolded protein response (UPR) pathway, downregulates p-AKT and Bcl-2, upregulates Bax, cleaved-caspase-9 and cleaved-caspase-3, inhibits the expression and activity of P-gp, and exerts synergistic anti-tumor effects with Doxorubicin (Adriamycin, ADM) (HY-15142A) and Cisplatin (DDP) (HY-17394). PROTAC PI3K/110β degrader-1 can be used in research related to multidrug-resistant cancers .
Cat. No.: HY-RS16948
Target:
Research Areas:
Adm Mouse Pre-designed siRNA Set A contains three designed siRNAs for Adm gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
